We all know that serialization deadlines are looming. While some companies have serialization projects underway, others are still waiting to get theirs started. Whatever the situation, there are still many unanswered questions about product protection, both domestically through the Drug Quality and Security Act (DQSA) and internationally through each country's regulations, and some of these answers are very hard to find (while others are still to be determined).
I recently sat down with two lead serialization consultants from Enterprise System Partners, a global consulting and project engineering company specializing in serialization and MES within the life science industry, to discuss many of the questions they’re receiving from their customers. Liam O’Riordan and Linda Murphy provided some clarity around certain aspects of the legislation and what it means both in the US and globally.